PTC Therapeutics, Inc.
PTCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001070081
In the last 90 days, PTC Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 384 institutions reported holding it in 13F filings for Q2 2026, worth $8.20B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 16, 2026
- $5.09B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $7.75M in total
- 10
- 13F holdersQ2 2026, +32 vs. previous quarter
- 384
- 13F valueReported value at the end of Q2 2026
- $8.20B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.73B
- +114.5% year over year
- Net income, FY2025
- $682.6M
- No comparable prior period
- Free cash flow, FY2025
- $702.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $357.8M
- +69.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.78M
- Shares sold short
- Change
- −524.0K
- −6.3% vs. previous
- Days to cover
- 7.50
- At average daily volume
Superinvestors holding PTCT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PTCT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by PTC Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 (view filing)5:20 PM ET | Oct 14 | 2 days | Schmertzler MichaelDirector | SSale | −2.50K | $59.61 | −$149.0K | −0.2%1.29M after | 2 lots10b5-1 |
| Oct 13, 2026 (view filing)5:20 PM ET | Oct 9 | 4 days | Boulding Mark ElliottEXEC. VP AND CLO | SSale | −192 | $64.26 | −$12.3K | −0.2%105.3K after | 10b5-1 |
| Oct 9, 2026 (view filing)5:20 PM ET | Oct 7 | 2 days | Schmertzler MichaelDirector | SSale | −2.50K | $63.39 | −$158.5K | −0.2%1.29M after | 2 lots10b5-1 |
| Oct 7, 2026 (view filing)5:20 PM ET | Oct 5-6 | 2 days | Boulding Mark ElliottEXEC. VP AND CLO | SSale | −2.07K | $64.06 | −$132.8K | −1.9%105.3K after | 2 lots10b5-1 |
| Oct 2, 2026 (view filing)5:20 PM ET | Sep 30 | 2 days | Steele Glenn Jr MD PhDDirector | SSale | −12.0K | $65.16 | −$781.9K | −34.8%22.5K after | 10b5-1 |
| Sep 18, 2026 (view filing)5:20 PM ET | Sep 16-17 | 2 days | Schmertzler MichaelDirector | SSale | −20.0K | $67.49 | −$1.35M | −1.5%1.30M after | 4 lots10b5-1 |
| Sep 11, 2026 (view filing)5:20 PM ET | Sep 9-10 | 2 days | Schmertzler MichaelDirector | SSale | −20.0K | $67.59 | −$1.35M | −1.5%1.32M after | 3 lots10b5-1 |
| Aug 28, 2026 (view filing)5:20 PM ET | Aug 26-27 | 2 days | Schmertzler MichaelDirector | SSale | −25.0K | $72.26 | −$1.81M | −1.8%1.34M after | 4 lots10b5-1 |
| Aug 21, 2026 (view filing)5:20 PM ET | Aug 19-20 | 2 days | Schmertzler MichaelDirector | SSale | −25.0K | $72.22 | −$1.81M | −1.8%1.36M after | 5 lots10b5-1 |
| Aug 19, 2026 (view filing)5:20 PM ET | Aug 17 | 2 days | Boulding Mark ElliottEXEC. VP AND CLO | SSale | −2.81K | $72.57 | −$204.1K | −2.6%105.3K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 384 holdersThe largest institutional positions in PTC Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,964,554 | $1.14B | 0.02% | +1,015,837+7.8% | Added |
| RTW Investments, LP | 7,746,415 | $631.9M | 5.39% | 00.0% | Unchanged |
| Jupiter Topco LLC | 7,236,402 | $590.2M | 0.24% | +7,236,402 | New |
| Vanguard Portfolio Management LLC | 4,928,111 | $402.0M | 0.02% | +123,517+2.6% | Added |
| State Street Corp | 4,598,952 | $375.1M | 0.01% | +252,433+5.8% | Added |
| Wellington Management Group LLP | 4,128,273 | $336.7M | 0.06% | +185,663+4.7% | Added |
| Vanguard Capital Management LLC | 3,739,127 | $305.0M | 0.01% | +62,871+1.7% | Added |
| Geode Capital Management, LLC | 2,207,376 | $180.1M | 0.01% | −2,578−0.1% | Reduced |
| Toronto Dominion Bank | 2,165,846 | $176.7M | 0.29% | −860,117−28.4% | Reduced |
| Westfield Capital Management Co LP | 1,956,156 | $159.6M | 0.52% | +1,956,156 | New |
Holders of 5% or more of PTCT
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of PTC Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 14.80%11.9M shares | +6.80 ppfrom 8.00% | Apr 17, 20252 filings | Dec 4, 2025 | SEC |
| Janus Henderson Group PLC | 13G/A | 8.70%7.19M shares | +2.70 ppfrom 6.00% | Feb 11, 20224 filings | May 15, 2026 | SEC |
| State Street Corp | 13G | 6.60%5.51M shares | +1.40 ppfrom 5.20% | Jan 24, 20244 filings | Nov 10, 2026 | SEC |
| Wellington Management Group LLP | 13G | 6.30%5.29M shares | +1.50 ppfrom 4.80% | Feb 4, 20218 filings | Nov 16, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.88%4.87M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |